RVL Pharmaceuticals plc (RVLP) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update
May 11, 2023 6:50 AM EDT-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million --
-- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year --
-- Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity --
-- Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end --
--... More
